Keele Research Repository

Article

Schmid, P, Abraham, J, Chan, S, Wheatley, D, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Nemsadze, G, Baird, RD, Park, YH, Hall, PS, Perren, T, Stein, RC, Mangel, L, Ferrero, J-M, Phillips, M, Conibear, J, Cortes, J, Foxley, A, de Bruin, EC, McEwen, R, Stetson, D, Dougherty, B, Sarker, S-J, Prendergast, A, McLaughlin-Callan, M, Burgess, M, Lawrence, C, Cartwright, H, Mousa, K and Turner, NC (2020) Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38 (5). 423 - 433.

Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Ruiz, I, Perelló, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Máhr, K, Schenker, M, Sohn, J, Lee, KS, Shepherd, CJ, Oelmann, E, Sarker, S-J, Prendergast, A, Marosics, P, Moosa, A, Lawrence, C, Coetzee, C, Mousa, K and Cortés, J (2019) Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5 (11). 1556 - 1556.

Conference or Workshop Item

Schmid, P, Abraham, J, Chan, S, Wheatley, D, Brunt, M ORCID: https://orcid.org/0000-0002-4797-5097, Nemsadze, G, Baird, R, Park, YH, Hall, P, Perren, T, Stein, RC, Laszlo, M, Ferrero, J-M, Phillips, M, Conibear, J, Sarker, S-J, Prendergast, A, Cartwrightx, H, Mousa, K and Turner, NC (2018) AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. In: 2018 ASCO Annual Meeting I, 01-05 Jun 2018.

Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Cabrero, IR, Perello, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Mahr, K, Schenker, M, Sohn, JH, Lee, KS, Sarker, S-J, Coetzee, C, Mousa, K and Castan, JC (2018) MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. In: 2017 San Antonio Breast Cancer Symposium, December 5-9 2017, San Antonio, Texas.